Table 1 Characteristics of patients in... | American Society of Hematology

Table 1

Characteristics of patients in the groups defined according to CCI (n = 1519)

Characteristics	CCI 2 (n = 589)		CCI 3-4 (n = 599)		CCI 5-6 (n = 229)		CCI ≥ 7 (n = 102)
Characteristics	No.	%	No.	%	No.	%	No.	%
Age, years
Median	39		57		68		72
Range	16-49		18-69		31-83		53-88
Sex
Female	206	35	258	43	96	42	42	41
Hemoglobin, g/dL
Median	11.7		12.6		12.7		12.3
Range	4.9-19.1		4.7-17.6		6.8-17.5		6.2-16.2
WBC × 10⁹/L
Median	111		67		46		57
Range	3.8-571		2.6-630		2.8-582		6.3-355
Platelets × 10⁹/L
Median	382		367		401		349
Range	39-2799		34-3020		70-2337		88-1993
EUTOS score
Low	493	90	528	90	211	94	91	89
High	93	10	61	10	14	6	11	11
Median time from diagnosis to random treatment assignment, days	14		18		18		20.5
Median observation time, months	65		72		66		62
Number of patients on
IM 400	145	25	149	25	67	29	35	34
IM 400+IFN	163	28	166	28	65	28	26	25
IM 400 + AraC	59	10	76	13	15	7	8	8
IM 400 after IFN	49	8	50	8	21	9	9	9
IM 800	173	29	158	26	61	27	24	24

Characteristics	CCI 2 (n = 589)		CCI 3-4 (n = 599)		CCI 5-6 (n = 229)		CCI ≥ 7 (n = 102)
Characteristics	No.	%	No.	%	No.	%	No.	%
Age, years
Median	39		57		68		72
Range	16-49		18-69		31-83		53-88
Sex
Female	206	35	258	43	96	42	42	41
Hemoglobin, g/dL
Median	11.7		12.6		12.7		12.3
Range	4.9-19.1		4.7-17.6		6.8-17.5		6.2-16.2
WBC × 10⁹/L
Median	111		67		46		57
Range	3.8-571		2.6-630		2.8-582		6.3-355
Platelets × 10⁹/L
Median	382		367		401		349
Range	39-2799		34-3020		70-2337		88-1993
EUTOS score
Low	493	90	528	90	211	94	91	89
High	93	10	61	10	14	6	11	11
Median time from diagnosis to random treatment assignment, days	14		18		18		20.5
Median observation time, months	65		72		66		62
Number of patients on
IM 400	145	25	149	25	67	29	35	34
IM 400+IFN	163	28	166	28	65	28	26	25
IM 400 + AraC	59	10	76	13	15	7	8	8
IM 400 after IFN	49	8	50	8	21	9	9	9
IM 800	173	29	158	26	61	27	24	24

IM 400, imatinib 400 mg/day; IM800, imatinib 800 mg/day; N, number of patients; WBC, white blood cells.